| Added by | celine.gongora |
|---|---|
| Group name | EquipeCG |
| Item Type | Journal Article |
| Title | Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer |
| Creator | Smith et al. |
| Author | Matthew R. Smith |
| Author | Fred Saad |
| Author | Simon Chowdhury |
| Author | Stéphane Oudard |
| Author | Boris A. Hadaschik |
| Author | Julie N. Graff |
| Author | David Olmos |
| Author | Paul N. Mainwaring |
| Author | Ji Youl Lee |
| Author | Hiroji Uemura |
| Author | Angela Lopez-Gitlitz |
| Author | Géralyn C. Trudel |
| Author | Byron M. Espina |
| Author | Youyi Shu |
| Author | Youn C. Park |
| Author | Wayne R. Rackoff |
| Author | Margaret K. Yu |
| Author | Eric J. Small |
| Abstract | BACKGROUND: Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis. METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo. All the patients continued to receive androgen-deprivation therapy. The primary end point was metastasis-free survival, which was defined as the time from randomization to the first detection of distant metastasis on imaging or death. RESULTS: A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo group). In the planned primary analysis, which was performed after 378 events had occurred, median metastasis-free survival was 40.5 months in the apalutamide group as compared with 16.2 months in the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 0.35; P<0.001). Time to symptomatic progression was significantly longer with apalutamide than with placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001). The rate of adverse events leading to discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group. The following adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%). CONCLUSIONS: Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204 .). |
| Publication | The New England Journal of Medicine |
| Volume | 378 |
| Issue | 15 |
| Pages | 1408-1418 |
| Date | Apr 12, 2018 |
| Journal Abbr | N. Engl. J. Med. |
| Language | eng |
| DOI | 10.1056/NEJMoa1715546 |
| ISSN | 1533-4406 |
| Library Catalog | PubMed |
| Extra | PMID: 29420164 |
| Tags | Adenocarcinoma, Aged, Aged, 80 and over, Androgen Antagonists, clinic, Disease Progression, Disease-Free Survival, Double-Blind Method, Exanthema, Humans, Male, Middle Aged, Neoplasm Metastasis, Proportional Hazards Models, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant, Thiohydantoins |
| Date Added | 2019/05/14 - 12:19:07 |
| Date Modified | 2019/05/14 - 13:25:54 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
